Provider Profile:
Ashley Matusz-Fisher, M.D.

School

• Wayne State University School of Medicine

Residency

• Carolinas Medical Center, Atrium Health

Fellowships

• Levine Cancer Institute, Atrium Health

Awards

• Selected Participant, ASCO/AACR Methods in Clinical Cancer Research Workshop (July 2021)
• Outstanding Fellow Recognition, North Carolina Oncology Association (September 2020)
• Fellow Merit Award, ASCO GI Symposium (January 2020)

Professional Memberships

• American Society of Hematology
• American Medical Association
• American Society of Clinical Oncology

• Matusz-Fisher A, Tan AR. Sacituzumab govitecan and other antibody-drug conjugates targeting trophoblast cell-surface antigen 2 (Trop-2) in breast cancer. Annals of Translational Medicine. 2022 Sept;10(18):1031.
• Matusz-Fisher A, Tan AR. Combination of HER2- targeted agents with immune checkpoint inhibitors in the treatment of HER2-positive breast cancer. Expert Opinion on Biological Therapy. 2021 Nov;22(3):385-395.
• Matusz-Fisher A, Tan AR. Targeted Therapy for Metastatic Triple-Negative Breast Cancer. In: Horizons in Cancer Research. Volume 79; 85-130. Nova Science Publishers, Hauppauge, NY, 2021.
• Patel JN, Robinson M, Jagosky M, Slaughter D, Arnall J, Jandrisevits E, Matusz-Fisher A, Atrash S, Paul B, Bhutani M, Voorhees P, Usmani SZ. Thromboembolism Incidence and Risk Factors in Multiple Myeloma After First Exposure to Immunomodulatory Drug-Based Regimens. Clin Lymphoma Myeloma Leuk. 2021 Mar;21(3):188-198.e2.
• Atrash S, Hamadeh I, Matusz‐Fisher A, Ndiaye A, Bhutani M, Voorhees PM, et al. Approaching the first relapse after autologous transplant in multiple myeloma. Adv CELL GENE Ther. 2021 Jan; 4 (1):e95.